3,4-dihydroxyphenylacetic acid has been researched along with Amyotrophic Lateral Sclerosis in 4 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In four human controls, four cases of Parkinson's disease and three cases of amyotrophic lateral sclerosis analysis of dopamine, noradrenaline, serotonin and the metabolites 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindoleacetic acid was performed in various segments of postmortem spinal cord." | 3.68 | Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. ( Gavranovic, M; Gsell, W; Jellinger, K; Riederer, P; Schmidtke, A; Sofic, E, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Golko-Perez, S | 1 |
| Mandel, S | 1 |
| Amit, T | 1 |
| Kupershmidt, L | 1 |
| Youdim, MB | 1 |
| Weinreb, O | 1 |
| Alexander, GM | 1 |
| Deitch, JS | 1 |
| Seeburger, JL | 1 |
| Del Valle, L | 1 |
| Heiman-Patterson, TD | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Klivenyi, P | 1 |
| Klein, AM | 1 |
| Dedeoglu, A | 1 |
| Albers, DS | 1 |
| Kowall, NW | 1 |
| Beal, MF | 1 |
| Sofic, E | 1 |
| Riederer, P | 1 |
| Gsell, W | 1 |
| Gavranovic, M | 1 |
| Schmidtke, A | 1 |
| Jellinger, K | 1 |
4 other studies available for 3,4-dihydroxyphenylacetic acid and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amyotrophic Lateral Sclerosis; Animals; Biogenic Monoamines; Corpus | 2016 |
Elevated cortical extracellular fluid glutamate in transgenic mice expressing human mutant (G93A) Cu/Zn superoxide dismutase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acid Transport System X-AG; Amyotrophic Lateral Sclerosis; Ani | 2000 |
Transgenic ALS mice show increased vulnerability to the mitochondrial toxins MPTP and 3-nitropropionic acid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amyotrophic Lateral Sc | 2001 |
Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Autopsy; Bio | 1991 |